← Back to Search

Virus Therapy

14 mcg VAX2012Q for Influenza

Phase 1
Waitlist Available
Research Sponsored by VaxInnate Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 21 days and 6 months post-vaccination
Awards & highlights

Study Summary

One dose of escalating strengths of an investigational influenza vaccine VAX2012Q (Quadrivalent Recombinant Hemagglutinin Seasonal Influenza Vaccine) will be evaluated for tolerability and immunogenicity in healthy adults 18-40 years of age.

Eligible Conditions
  • Influenza

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~21 days and 6 months post-vaccination
This trial's timeline: 3 weeks for screening, Varies for treatment, and 21 days and 6 months post-vaccination for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety
Secondary outcome measures
Immunogenicity

Trial Design

7Treatment groups
Experimental Treatment
Group I: 8 mcg VAX2012Q repeatedExperimental Treatment1 Intervention
8 mcg VAX2012Q
Group II: 8 mcg VAX2012QExperimental Treatment1 Intervention
8 mcg VAX2012Q
Group III: 4 mcg VAX2012QExperimental Treatment1 Intervention
4 mcg VAX2012Q
Group IV: 18 mcg VAX2012QExperimental Treatment1 Intervention
18 mcg VAX2012Q
Group V: 14 mcg VAX2012QExperimental Treatment1 Intervention
14 mcg VAX2012Q
Group VI: 12 mcg VAX2012Q repeatedExperimental Treatment1 Intervention
12 mcg VAX2012Q
Group VII: 12 mcg VAX2012QExperimental Treatment1 Intervention
12 mcg VAX2012Q

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

VaxInnate CorporationLead Sponsor
11 Previous Clinical Trials
1,838 Total Patients Enrolled
C. Jo White, MDStudy DirectorVaxInnate Corporation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention
2014. "Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02015494.
All > Flu
~29 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top